Leukemia Research
Volume 26, Issue 11 , Pages 1043-1046 , November 2002

Cladribine induces immunophenotypical changes in bone marrow mast cells from mastocytosis: Report of a case of mastocytosis associated with a lymphoplasmacytic lymphoma

  • Luis Escribano

      Affiliations

    • Hospital Ramón y Cajal, Mast Cell Unit, Carretera de Colmenar Km 9.1, Madrid 28034, Spain
    • Corresponding Author InformationCorresponding author.
    • ,
  • Jaime Pérez de Oteyza

      Affiliations

    • Hospital Ramón y Cajal, Mast Cell Unit, Carretera de Colmenar Km 9.1, Madrid 28034, Spain
    • ,
  • Rosa Núñez

      Affiliations

    • Hospital Ramón y Cajal, Mast Cell Unit, Carretera de Colmenar Km 9.1, Madrid 28034, Spain
    • ,
  • Alberto Orfao

      Affiliations

    • Centro de Investigación del Cáncer, Universidad de Salamanca, Salamanca, Spain

Received 4 March 2002 ,Accepted 10 April 2002.

References 

  1. Parker RI. Hematologic aspects of systemic mastocytosis. Hematol. Oncol. Clin. N. Am. 2000;14:557–568
  2. Sperr WR, Horny HP, Lechner K, Valent P. Clinical and biologic diversity of leukemias occurring in patients with mastocytosis. Leuk. Lymphoma. 2000;37:473–486
  3. Cooper AJ, Winkelmann RK, Wiltsie JC. Hematologic malignancies occurring in patients with urticaria pigmentosa. J. Am. Acad. Dermatol. 1982;7:215–220
  4. Cox JV, Balaban EP, Demian SE, Sheehan RG. An eosinophilic fibrohistiocytic lesion of bone marrow in a patient with Hodgkin’s disease: a potential for morphologic confusion. Cancer. 1991;68:1824–1827
  5. Saletti P, Ghielmini M, Scali G, Pedrinis E, Guéneau M, Cavalli F. Hodgkin’s and Castleman’s disease in a patient with systemic mastocytosis. Ann. Hematol. 1999;78:97–100
  6. Sanz MA, Valcarcel D, Sureda A, Muno L, Rodriguez-Espinosa J, et al.  Systemic mast cell disease associated with B-chronic lymphocytic leukemia. Haematologica. 2001;86:1106–1107
  7. Petrella T, Depret O, Arnould L, Maynadie M, Guy H, Dalac S, et al.  Systemic mast cell disease associated with hairy cell leukaemia. Leuk. Lymphoma. 1997;25:593–595
  8. Jackson A, Burton IE. A case of POEMS syndrome associated with essential thrombocythaemia and dermal mastocytosis. Postgrad. Med. J. 1990;66:761–767
  9. Hagen W, Schwarzmeier J, Walchshofer S, Zojer N, Chott A, Sillaber C, et al.  A case of bone marrow mastocytosis associated with multiple myeloma. Ann. Hematol. 1998;76:167–174
  10. Cheson BD, Sorensen JM, Vena DA, Montello MJ, Barrett JA, Damasio E, et al.  Treatment of hairy cell leukemia with 2-chlorodeoxyadenosine via the group C protocol mechanism of the National Cancer Institute: a report of 979 patients. J. Clin. Oncol. 1998;16:3007–3015
  11. Tefferi A, Li CY, Butterfield JH, Hoagland HC. TI—treatment of systemic mast-cell disease with cladribine. N. Engl. J. Med. 2001;344:307–309
  12. Sperr W, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny H-P, et al.  Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk. Res. 2001;25:529–536
  13. Orfao A, Escribano L, Villarrubia J, Velasco JL, Cerveró C, Ciudad J, et al.  Flow cytometric analysis of mast cells from normal and pathological human bone marrow samples: identification and enumeration. Am. J. Pathol. 1996;149:1493–1499
  14. Escribano L, Orfao A, Dı́az Agustı́n B, Villarrubia J, Cerveró C, López A, et al.  Indolent systemic mast cell disease in adults: immunophenotypic characterization and its diagnostic implications. Blood. 1997;91:2731–2736
  15. Escribano L, Orfao A, Villarrubia J, Dı́az Agustı́n B, Cerveró C, Rı́os A, et al.  Immunophenotypic characterization of human bone marrow mast cells: a flow cytometric study of normal and pathological bone marrow samples. Ann. Cell. Pathol. 1998;16:151–159
  16. Escribano L, Orfao A, Dı́az Agustı́n B, Cerveró C, Herrero S, Villarrubia J, et al.  Human bone marrow mast cells from indolent systemic mast cell disease constitutively express increased amounts of the CD63 protein on their surface. Cytometry. 1998;34:223–228
  17. Dı́az Agustı́n B, Escribano L, Bravo P, Herrero S, Núñez R, Navalón R, et al.  The CD69 early activation molecule is overexpressed in human bone marrow mast cells from adults with indolent systemic mast cell disease. Br. J. Haematol. 1999;106:400–405
  18. Valent P, Horny H-P, Escribano L, Longley-Bj J, Li CL, Schwartz LB, et al.  Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk. Res. 2001;25:603–625
  19. Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk. Res. 2001;25:543–551
  20. Hoffman MA, Janson D, Rose E, Rai KR. Treatment of hairy-cell leukemia with cladribine: response, toxicity, and long-term follow-up. J. Clin. Oncol. 1997;15:1138–1142
  21. Gorski A, Grieb P, Korczak-Kowalska G, Wierzbicki P, Stepien-Sopniewska B, Mrowiec T. Cladribine (2-chloro-deoxyadenosine, CDA): an inhibitor of human B- and T-cell activation in vitro. Immunopharmacology. 1993;26:197–202

PII: S0145-2126(02)00073-5

Leukemia Research
Volume 26, Issue 11 , Pages 1043-1046 , November 2002

Article Tools

* Image Usage & Resolution